Patents Represented by Attorney, Agent or Law Firm J. Antonio Garcia-Rivas
  • Benzamide potassium channel inhibitors
    Patent number: 6194458
    Abstract: This invention relates to benzamide potassium channel inhibitors of general structural Formula I. The compounds of this invention are useful in the treatment of autoimmune diseases, the prevention of rejection of foreign organ transplants and related afflictions, diseases and illnesses, and cardiac arrhythmias. Also within the scope of this invention are pharmaceutical formulations comprising a compound of Formula I and a pharmaceutical carrier, as well as pharmaceutical formulations comprising a compound of Formula I, one or more immunosuppressive compounds and a pharmaceutical carrier.
    Type: Grant
    Filed: October 21, 1999
    Date of Patent: February 27, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Robert K. Baker, Jianming Bao, Frank Kayser, Andrew Kotliar, William H. Parsons, Kathleen M. Rupprecht, Christopher F. Claiborne, David A. Claremon, Nigel Liverton, Wayne J. Thompson
  • Tyrosine kinase inhibitors
    Patent number: 6162804
    Abstract: The present invention relates to benzinidazole compounds which inhibit tyrosine kinase enzymes, compositions which contain tyrosine kinase inhibiting compounds and methods of using tyrosine kinase inhibitors to treat tyrosine kinase-dependent diseases/conditions such as angiogenenesis, cancer, atherosclerosis, diabetic retinopathy or autoimmune diseases, in mammals.
    Type: Grant
    Filed: March 11, 1999
    Date of Patent: December 19, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Mark T. Bilodeau, April M. Cunningham, Randall W. Hungate, Timothy J. Koester
  • Inhibitors of farnesyl-protein transferase
    Patent number: 6127366
    Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the famesylation of the oncogene protein Ras.
    Type: Grant
    Filed: October 5, 1998
    Date of Patent: October 3, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Byeong M. Kim, Anthony W. Shaw, Samuel L. Graham, S. Jane deSolms, Terrence M. Ciccarone
  • Tetracyclic triterpene derivatives with immunosuppressant activity
    Patent number: 6100293
    Abstract: The compounds of Formula I ##STR1## are useful as immunosuppressive agents.
    Type: Grant
    Filed: October 1, 1998
    Date of Patent: August 8, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Robert K. Baker, Jianming Bao, Frank Kayser, Shouwu Miao, William H. Parsons, Kathleen M. Rupprecht
  • Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
    Patent number: 6080870
    Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.
    Type: Grant
    Filed: October 1, 1998
    Date of Patent: June 27, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Neville J. Anthony, Robert P. Gomez, Gerald E. Stokker, John S. Wai, Theresa M. Williams, Wasyl Halczenko, John H. Hutchinson, Steven D. Young, Kelly M. Solinsky
  • Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
    Patent number: 6063930
    Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.
    Type: Grant
    Filed: October 2, 1998
    Date of Patent: May 16, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Christopher J Dinsmore, Neville J. Anthony, Gerald E. Stokker, Robert P. Gomez
  • Immunosuppressant tricyclic compounds
    Patent number: 6051590
    Abstract: The compounds of Formula I are useful as immunosuppressive agents.
    Type: Grant
    Filed: May 13, 1999
    Date of Patent: April 18, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Jianming Bao, Frank Kayser, Robert K. Baker, Shouwu Miao, William H. Parsons, Kathleen M. Rupprecht
  • Inhibitors of farnesyl-protein transferase
    Patent number: 6051574
    Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.
    Type: Grant
    Filed: February 10, 1999
    Date of Patent: April 18, 2000
    Assignee: Merck & Co., Inc.
    Inventor: Neville J. Anthony
  • Pyridine propanoic acid derivatives
    Patent number: 6022972
    Abstract: This invention relates to a key intermediate in the synthesis of an endothelin antagonist the synthesis of this key intermediate via an asymmetric conjugate addition reaction.
    Type: Grant
    Filed: July 14, 1998
    Date of Patent: February 8, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Paul N. Devine, Richard D. Tillyer, Richard M. Heid, Jr., David M. Tschaen
  • Immunosuppressant tetracyclic triterpenes
    Patent number: 6022890
    Abstract: The compounds of Formula I ##STR1## are useful as immunosuppressive agents.
    Type: Grant
    Filed: October 21, 1998
    Date of Patent: February 8, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Jianming Bao, Robert K. Baker, Frank Kayser, Andrew Kotliar, William H. Parsons, Kathleen M. Rupprecht, Peter J. Sinclair
  • Triterpene derivatives with immunosuppressant activity
    Patent number: 5998408
    Abstract: The compounds of Formula I ##STR1## are useful as immunosuppressive agents.
    Type: Grant
    Filed: October 8, 1997
    Date of Patent: December 7, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Robert K. Baker, Frank Kayser, Jianming Bao, Andrew Kotliar, William H. Parsons, Kathleen M. Rupprecht
  • Substituted azetidinones as anti-inflammatory and antidegenerative agents
    Patent number: 5952321
    Abstract: New substituted azetidinones of the general Formula (I) which have been found to be potent elastase inhibitors and thereby useful anti-inflammatory and antidegenerative agents are described, wherein n is
    Type: Grant
    Filed: December 12, 1996
    Date of Patent: September 14, 1999
    Assignee: Merck & Co., Inc.
    Inventors: James Doherty, Conrad Dorn, Philippe Durette, Paul Finke, Malcolm Maccoss, Sander Mills, Shrenik Shah, Soumya Sahoo, William Hagmann, Scott Polo
  • Triterpene derivatives with immunosuppressant activity
    Patent number: 5952371
    Abstract: The compounds of Formula I ##STR1## are useful as iumnunosuppressive agents.
    Type: Grant
    Filed: October 8, 1997
    Date of Patent: September 14, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Robert K. Baker, Frank Kayser, Jianming Bao, Andrew Kotliar, William H. Parsons, Kathleen M. Rupprecht
  • Inhibitors of farnesyl-protein transferase
    Patent number: 5939557
    Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.
    Type: Grant
    Filed: March 25, 1997
    Date of Patent: August 17, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Neville J. Anthony, Robert P. Gomez, Kelly M. Solinsky
  • Method for the treatment of preterm labor
    Patent number: 5929071
    Abstract: The invention is directed to a method useful in the treatment of preterm labor, dysmenorrhea and for the stoppage of labor preparatory to cesarean delivery.
    Type: Grant
    Filed: June 30, 1997
    Date of Patent: July 27, 1999
    Assignee: Merck & Co., Inc.
    Inventor: Joseph J. Salata, Jr.
  • Process for phosphodiesterase IV inhibitors
    Patent number: 5919937
    Abstract: The invention encompasses a novel process for the formation of enantiomerically enriched mixtures of compounds of Formula I, which are useful precursors in the synthesis of phosphodiestersae IV inhibitors.
    Type: Grant
    Filed: October 7, 1998
    Date of Patent: July 6, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Joseph E. Lynch, Kenneth M. Wells, Yao-Jun Shi
  • Triterpene derivatives with immunosuppressant activity
    Patent number: 5883119
    Abstract: The compounds of Formula I ##STR1## are useful as immunosuppressive agents.
    Type: Grant
    Filed: October 16, 1996
    Date of Patent: March 16, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Robert K. Baker, Frank Kayser, Jianming Bao, William H. Parsons, Kathleen M. Rupprecht
  • Triterpene derivatives with immunosuppressant activity
    Patent number: 5874594
    Type: Grant
    Filed: October 8, 1997
    Date of Patent: February 23, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Robert K. Baker, Frank Kayser, Jianming Bao, Andrew Kotliar, William H. Parsons, Kathleen M. Rupprecht
  • Process for the crystalization of losartan
    Patent number: 5859258
    Abstract: Losartan potassium is an angiotensin II antagonist useful in the treatment of hypertension and congestive heart failure. ##STR1## This invention relates to the process for the controlled crystallization of losartan potassium utilizing anti-solvent addition combined with massive seeding in order to obtain the desired crystal morphology and bulk physical properties necessary for successful formulation.
    Type: Grant
    Filed: October 28, 1997
    Date of Patent: January 12, 1999
    Assignee: Merck & Company, Inc.
    Inventors: Patrick Breen, Erik A. Dienemann, Albert D. Epstein, Karen A. Larson, Michael T. Kennedy, Hari Mahadevan
  • Chiral auxilary for stereoselective alkylations
    Patent number: 5856519
    Abstract: This invention relates to a method for the stereoselective synthesis of a 2-aryloxycarboxylic acid using a chiral auxiliary to enhance the stereoselectivity of the alkylation of the .alpha.-halo acid with an aryloxy group.
    Type: Grant
    Filed: September 23, 1997
    Date of Patent: January 5, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Paul N. Devine, Richard M. Heid, Jr., David M. Tschaen